OPTIMA II trial

Ari Rosenberg: Our OPTIMA II trial is out in JAMA Oncology

Ari Rosenberg, Medical Oncologist and Assistant Professor at the University of Chicago, shared a post on X:         ,

“Excited that our OPTIMA II trial is out in JAMA Oncology!  

Neoadjuvant nivolumab/chemotherapy -> response-adaptive treatment for HPV+ oropharyngeal cancer.”

Proceed to the article.
Source: Ari Rosenberg/X

Ari Rosenberg cancer HPV+ oropharyngeal cancer JAMA Oncology nivolumab OncoDaily oncologist Oncology OPTIMA II trial oropharyngeal cancer response-adaptive treatment University of Chicago